Claim Review: Effectiveness of Ivermectin, Mebendazole, and Fenbendazole as Cancer Treatments

Introduction

A recent article published on October 16, 2024, claims that a peer-reviewed study in the International Journal of Orthomolecular Medicine shows that ivermectin, mebendazole, and fenbendazole are effective treatments for cancer. This claim has garnered significant attention, particularly in the context of alternative medicine and the COVID-19 pandemic.

The Claim

The article states that Drs. William Makis, Paul Marik, Ilyes Baghli, and other scientists from the Frontline COVID-19 Critical Care Alliance (FLCCC) conducted a study demonstrating the anticancer benefits of these three deworming drugs. The study was published on September 19, 2024, and suggests that these drugs could be a breakthrough in cancer treatment, potentially replacing conventional treatments like chemotherapy and radiation.

Analysis of the Claim

The International Journal of Orthomolecular Medicine is a reputable source, and the study was peer-reviewed, which adds credibility to the claim. However, it is important to note that a single study, even if peer-reviewed, does not constitute definitive proof. Further research and clinical trials are necessary to validate these findings and determine the safety and efficacy of these drugs for cancer treatment.

Ivermectin, mebendazole, and fenbendazole are primarily used as antiparasitic drugs. While there is some preliminary evidence suggesting their potential anticancer properties, the mechanisms by which they might work against cancer are not fully understood. More studies are needed to explore these mechanisms and to assess the long-term effects of these drugs on cancer patients.

Related Studies and Evidence

Several studies have explored the potential of ivermectin and other antiparasitic drugs in cancer treatment. For example, a study published in the journal Frontiers in Pharmacology suggests that ivermectin m ay have anticancer effects by inhibiting certain cellular pathways. Similarly, a review in the journal Cancers  discusses the potential of mebendazole as an anticancer agent.

However, these studies are preliminary, and more extensive clinical trials are needed to confirm the efficacy and safety of these drugs in cancer treatment.

Conclusion

While the claim that ivermectin, mebendazole, and fenbendazole are effective cancer treatments is based on a peer-reviewed study, it is premature to conclude that these drugs are a definitive solution for cancer. Further research and clinical trials are necessary to validate these findings and to ensure the safety and efficacy of these treatments. Patients should consult with their healthcare providers before considering any alternative treatments.